|
WO2018183881A1
|
|
Methods and compositions for self-regulated release of active pharmaceuticals ingredients
|
|
WO2017070576A1
|
|
Methods and compositions for regulating conversion of a prodrug to an active pharmaceutical ingredient
|
|
WO2017040607A1
|
|
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
|
AU2015264950A1
|
|
Methods and compositions for deterring abuse of opioid containing dosage forms
|
|
AU2015274936A1
|
|
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
|
|
EP3016645A1
|
|
Methods and compositions for deterring abuse
|
|
CN108743549A
|
|
The self-regulation of active pharmaceutical ingredient discharges
|
|
WO2014022541A1
|
|
Stabilization of one-pot methamphetamine synthesis systems
|
|
AU2013206525A1
|
|
Methods and compositions for deterring abuse of opioid containing dosage forms
|
|
AU2012201450A1
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
WO2012021819A1
|
|
Optimized niacin compositions in pharmaceutical products
|
|
WO2011079248A1
|
|
Pharmaceutical compositions for deterring misuse, abuse, and diversion
|
|
CA2775890A1
|
|
Methods and compositions for deterring abuse
|
|
US2008152595A1
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
IL183362D0
|
|
Compositions for deterring abuse of orally administered pharmaceutical products
|
|
US2007231268A1
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
EP1993519A2
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
US2006110327A1
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
US2006177380A1
|
|
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
|
US2006167258A1
|
|
Production of opioid analgesics
|
